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Introduction: Recent studies from our group suggest that extracellular matrix (ECM) 
deposition and fibrosis characterize the peri−urethral prostate tissues of some men 
suffering from Lower Urinary Tract Symptoms (LUTS). Fibrosis can generally be regarded 
as an errant wound−healing process in response to chronic inflammation, and studies 
have shown that the aging prostate tissue microenvironment is rich with inflammatory 
cells and proteins. However, it is unclear whether these same inflammatory proteins, 
particularly CXC−type chemokines, can mediate myofibroblast phenoconversion and the 
ECM deposition necessary for the development of prostatic tissue fibrosis.    
Methods: Peri−urethral prostate tissues were disaggregated and subjected to FACS for 
expression of CD45 and collagen I. Primary stromal fibroblasts were cultured from 
explanted human peri−urethral prostatic tissues. N1 immortalized or primary prostate 
stromal fibroblasts were treated in serum−free defined media with TGF−β, CXCL5, 
CXCL8, or CXCL12 and evaluated using immunofluorescence or qRT−PCR for αSMA, 
collagen I, collagen III, vimentin, calponin, and tenascin protein and transcript expression, 
and by gel contraction assays for functional myofibroblast phenoconversion.  The 
specificity of these responses to treatment with CXCL12 was assessed using a small 
molecule inhibitor, AMD3100, of the CXCL12 receptor, CXCR4.  
Results: The results of these studies showed that peri−urethral prostate tissues 
comprised both myofibroblastic and fibroblastic cell types, but that CD45+/collagen I+ 
fibrocytic cells were identified exclusively in peri−urethral tissues from men suffering from 
LUTS.  Both N1 immortalized and primary prostate stromal fibroblasts exhibited 
complete and functional myofibroblast phenoconversion and were induced to express 
collagen I, collagen III and αSMA gene transcripts and proteins in response to treatment 
with CXC−type chemokines, even in the absence of exogenous TGF−β1.  
Conclusions: These findings suggest that CXC−type chemokines, particularly CXCL12, 
can efficiently and completely mediate myofibroblast phenoconversion and may thereby 
promote fibrotic changes in prostate tissue architecture associated with the development 
and progression of male lower urinary tract dysfunction. 
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